ArticleThe Journal of antimicrobial chemotherapy2026
Using biofilm-targeting local antibiotics to treat recalcitrant medical device-associated infections: driveline infection as a model.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Driveline infection, exemplifying medical device-associated infection, is a difficult-to-treat complication of ventricular assist device implantation in which biofilm formation underlies both infection onset and recurrence. Although clinical experience remains limited, treatment success has been reported in cases where local antibiotics at high concentrations were used in combination with surgical debridement and/or device reimplantation. We recently identified the low metabolic state of biofilm cells as the central mechanism underlying the high antimicrobial resistance of staphylococcal biofilms and as a potential therapeutic target for driveline infections. We hypothesize that rationally combining weakly and strongly metabolism-dependent antibiotics at high concentrations for an extended period may eradicate staphylococcal biofilms, including the embedded tolerant and persister cells. If clinically validated, this strategy may hold the key to achieving long-term treatment success in many medical device-associated infections, including the driveline infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.